Latest Developments in Global Idiopathic Pulmonary Fibrosis Treatment Market

Customize Your Report Customize Your Report Buy Now Buy Now Free Sample Report Free Sample Report
back-icon

Back to Report
Home Pharmaceutical Global Idiopathic Pulmonary Fibrosis Treatment Market Latest Developments
Request for TOC Request for TOC Speak to Analyst Speak to Analyst Free Sample Report Free Sample Report Inquire Before Buying Inquire Before Buy Now Buy Now

Latest Developments in Global Idiopathic Pulmonary Fibrosis Treatment Market

  • Pharmaceutical
  • Jun 2021
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60
Buy Now Buy Now Request for Sample Request for Sample
Nucleus Nucleus

  • In September 2024, Boehringer Ingelheim announced that its FIBRONEER-IPF study of nerandomilast successfully met its primary endpoint, prompting plans for a new drug application for IPF treatment.
  • In May 2024, Ferrer expanded its distribution agreement with United Therapeutics to obtain worldwide rights for treprostinil inhalation solution, targeting potential indications for Idiopathic and Progressive Pulmonary Fibrosis
  • In September 2024, Boehringer Ingelheim announced that its FIBRONEER-IPF study of nerandomilast successfully met its primary endpoint, prompting plans for a new drug application for IPF treatment.
  • In May 2024, Ferrer expanded its distribution agreement with United Therapeutics to obtain worldwide rights for treprostinil inhalation solution, targeting potential indications for Idiopathic and Progressive Pulmonary Fibrosis

Browse Related Pages

Banner